AZN250110P69000
- 3.80
- 0.000.00%
アストラゼネカのニュース一覧
Astra, Merck Drugs Set to Shake Up Liver Cancer Treatment
Why Astrazeneca (AZN) Is a Top Growth Stock for the Long-Term
TD Cowenはアストラゼネカ(AZN.US)のレーティングを強気に据え置き
TD CowenのアナリストSteve Scalaは$AstraZeneca(AZN.US)$のレーティングを強気に据え置き。TipRanksのデータによると、このアナリストの最近1年間の的中率は56.7%、平均リターンは5.2%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供している独立第三者です。提供された情報はあくまで参考情
交银国际：维持和黄医药“买入”评级 目标价升至44港元
J&J Lung Cancer Treatment Extends Lives Versus AstraZeneca Drug | NYSE:JNJ
J&J Rybrevant/Lazcluze Combo Bests AstraZeneca's Tagrisso in NSCLC
Johnson & Johnson Reports 'Statistically Significant' Data From Trial of Rybrevant, Lazcluze Combination to Treat Lung Cancer
Asher Bio Announces Clinical Supply Agreement With AstraZeneca To Enable Evaluation Of Etakafusp Alfa In Combination With Rilvegostomig In A Global Phase 1b/2 Study In Non-Small Cell Lung Cancer
Berenberg Maintains AstraZeneca's Rating on Promising 2025 Pipeline
FDA Issues First Draft Guidance on Use of AI in Drug, Medical Device Development
Vaccine Stocks Gain Amid Uptick in Flu, COVID-19, RSV
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
AstraZeneca PLC Stock Flat Friday
阿斯利康(AZN.US)PD-1/TIGIT双抗启动III期临床
阿斯利康(AZN.US)“奥希替尼”在中国获批新适应症
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
Reported Wednesday, HUTCHMED And AstraZeneca's ORPATHYS-TAGRISSO Therapy Advances In China With Priority NDA Status For MET-Amplified Lung Cancer
Takeda-backed Ascentage Pharma Files for $100M IPO